These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The fraction of sensitization among lung transplant recipients in a transplant center in Japan. Kumata S; Hirama T; Watanabe Y; Oishi H; Niikawa H; Akiba M; Tikkanen J; Okada Y BMC Pulm Med; 2020 Oct; 20(1):256. PubMed ID: 33008353 [TBL] [Abstract][Full Text] [Related]
9. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients. Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718 [TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival. Bogyó LZ; Török K; Illés Z; Szilvási A; Székely B; Bohács A; Pipek O; Madurka I; Megyesfalvi Z; Rényi-Vámos F; Döme B; Bogos K; Gieszer B; Bakos E Respir Res; 2024 Jul; 25(1):262. PubMed ID: 38951782 [TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies. Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404 [No Abstract] [Full Text] [Related]